The following
IPOs are expected to price this week
:
Berry Plastics Group
(
BERY
), which manufactures plastic goods and containers for consumer
applications, plans to raise $500 million by offering 29.4
million shares at a price range of $16.00 to $18.00. At the
midpoint of the proposed range, Berry Plastics Group would
command a market value of $2.0 billion. Berry Plastics Group,
which was founded in 1967, booked $4.8 billion in sales over the
last 12 months. The Evansville, IN-based company plans to list on
the NYSE under the symbol BERY. BofA Merrill Lynch, Citi,
Barclays and Deutsche Bank are the joint bookrunners on the deal.
Dave & Buster's Entertainment
(
PLAY
), which operates 60 casual dining restaurants with large arcade
areas, plans to raise $100 million by offering 7.7 million shares
at a price range of $12.00 to $14.00. At the midpoint of the
proposed range, Dave & Buster's Entertainment would
command a market value of $364 million. Dave & Buster's
Entertainment, which was founded in 1982, booked $576 million in
sales over the last 12 months. The Dallas, TX-based company plans
to list on the NASDAQ under the symbol PLAY. Goldman Sachs,
Jefferies & Co. and Piper Jaffray are the joint
bookrunners on the deal.
Fleetmatics Group
(
FLTX
), which is a leading SaaS provider of fleet management
solutions, plans to raise $125 million by offering 7.8 million
shares at a price range of $15.00 to $17.00. At the midpoint of
the proposed range, Fleetmatics Group would command a market
value of $588 million. Fleetmatics Group, which was founded in
2004, booked $108 million in sales over the last 12 months. The
Dublin, Ireland-based company plans to list on the NYSE under the
symbol FLTX. Barclays and BofA Merrill Lynch are the joint
bookrunners on the deal.
GlobeImmune
(
GBIM
), which is developing therapeutic drugs for pancreatic cancer
and hepatitis B and C, plans to raise $60 million by offering 5.0
million shares at a price range of $11.00 to $13.00. At the
midpoint of the proposed range, GlobeImmune would command a
market value of $207 million. GlobeImmune, which was founded in
1995, booked $9 million in sales over the last 12 months. The
Louisville, CO-based company plans to list on the NASDAQ under
the symbol GBIM. Wells Fargo Securities and Piper Jaffray are the
joint bookrunners on the deal.
Javelin Mortgage Investment
(
JMI
), an ARMOUR-managed REIT newly formed to acquire
mortgage-related assets, plans to raise $125 million by offering
6.3 million shares at a price of $20.00. At the midpoint of the
proposed range, Javelin Mortgage Investment would command a
market value of $130 million. Javelin Mortgage Investment was
founded in 2012. The Vero Beach, FL-based company plans to list
on the NYSE under the symbol JMI. Deutsche Bank, Citi, Barclays
and Credit Suisse are the joint bookrunners on the deal.
LifeLock
(LOCK), an online provider of identity theft protection services,
plans to raise $165 million by offering 15.7 million shares at a
price range of $9.50 to $11.50. At the midpoint of the proposed
range, LifeLock would command a market value of $981 million.
LifeLock, which was founded in 2005, booked $228 million in sales
over the last 12 months. The Tempe, AZ-based company plans to
list on the NYSE under the symbol LOCK. Goldman Sachs, BofA
Merrill Lynch and Deutsche Bank are the joint bookrunners on the
deal.
Luxfer Holdings
(LXFR), a global materials firm specializing in aluminum,
magnesium and zirconium, plans to raise $104 million by offering
8.0 million shares at a price range of $12.00 to $14.00. At the
midpoint of the proposed range, Luxfer Holdings would command a
market value of $341 million. Luxfer Holdings, which was founded
in 1996, booked $534 million in sales over the last 12 months.
The Salford, United Kingdom-based company plans to list on the
NYSE under the symbol LXFR. Credit Suisse and Jefferies &
Co. are the joint bookrunners on the deal.
Regulus Therapeutics
(RGLS), an early stage biotech developing microRNAs treatments
for multiple serious diseases, plans to raise $50 million by
offering 4.5 million shares at a price range of $10.00 to $12.00.
At the midpoint of the proposed range, Regulus Therapeutics would
command a market value of $239 million. Regulus Therapeutics,
which was founded in 2007, booked $14 million in sales over the
last 12 months. The San Diego, CA-based company plans to list on
the NASDAQ under the symbol RGLS. Lazard Capital Markets, Cowen
& Company and BMO Capital Markets are the joint
bookrunners on the deal.
Renaissance Capital will have
Pre-IPO Research
available on each of these upcoming IPOs prior to its pricing.
Last week, there were 3
IPO pricings
. Qualys (QLYS), which provides cloud-based IT security and
compliance software solutions, was the week's winner, ending up
18% from its IPO price.